As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&amp;J’s lead in MM, shaves hours off infusion time. How will patients react, in the realm of #MultipleMyeloma where standard of care often involve doublet if not triplet therapies?  https://t.co/LS5bXqAY2k $JNJ https://t.co/LTCV9kGZQ1